What Could Lift ISRG Stock?
Intuitive Surgical (ISRG) stock has lost 8.2% over the past twelve months, while the S&P 500 returned 17.1%. If you own it, you have watched the market move on without you, and if you do not, the lower price may look tempting. Either way, you are counting on the business behind the da Vinci systems. So what would Intuitive have to sell more of for the stock to climb again?
Intuitive’s Gain Would Come Mainly From Higher Revenue
Intuitive would have to sell more of the instruments hospitals buy for each da Vinci procedure. Its Instruments and Accessories segment is the largest part of the business, with $6.0 billion of the company’s $10.1 billion in fiscal 2025 revenue. If revenue keeps growing alongside an expansion in the stock’s valuation multiple, the stock would be worth about 78.9% more in three years on our assumptions. That is a scenario built on the company’s trailing numbers, and it is not a forecast.
The table sets Intuitive’s figures today against the same figures three years out in the scenario.
| Today | In three years (scenario) | |
|---|---|---|
| Revenue | $11.0 billion | $17.9 billion |
| Net margin | 28.4% | 28.0% |
| Earnings | $3.1 billion | $5.0 billion |
| P/E | 45.8 | 51.3 |
| Share price | $406.48 | $727.06 |
About 83% of that gain comes from higher revenue, so it comes from the business. Another 19% comes from a higher P/E, and that part is an assumption. We assume a higher P/E of 51.3 in year three—recovering part of the way toward the stock’s three-year average of 67.7 (measured at quarter-ends with readings above 100 excluded)—because today’s multiple sits well below that baseline. A slightly lower net margin takes about 3% back.
Is Intuitive Still Growing Its Procedures?
Yes, so far: total procedures grew 16% in fiscal Q2 2026, management said on the July 16, 2026 call. Hospitals are also moving to the newest machine, da Vinci 5. It made up 246 of the 468 systems placed that quarter.
But management’s own outlook does not test our scenario directly. The scenario assumes revenue grows 17.6% a year for three years, off the trailing pace. Management’s fiscal 2026 guide of about 14.5% is for growth in da Vinci procedures, not revenue, and it covers one year. Management also said growth in the US moderated, mostly in procedures that patients can put off.
The instruments Intuitive would have to sell more of also face a pricing change. From the first half of 2027, the company plans to lower what customers pay per use on some of them. Management has not yet put a figure on the effect.
How Much Would Intuitive Return In Weaker Cases?
Intuitive stock would return less when one assumption misses, but it would still show a gain in every case in the table below. The table gives the three-year upside when one assumption changes and the others stay as they are.
| If instead | Upside |
|---|---|
| Nothing changes (the scenario) | 78.9% |
| Revenue grows two points a year slower | 69.9% |
| The margin returns to its three-year average | 71.6% |
| The P/E stays where it is today | 59.7% |
| Five years at the same pace instead of three | 147.2% |
| The next fiscal year grows at management’s guided pace | 74.2% |
Of the misses in the table, you would lose the most gain if the P/E stays where it is today. Revenue growing two points a year slower would cost you less. The net margin is a small drag too, because we assume it slips from the trailing level toward its three-year average.
Sales are the main source of the gain, though the valuation multiple carries more downside risk: a flat P/E would trim returns more than revenue growing two points slower. Even so, revenue would have to shrink about 3.2% a year before three years of owning the stock returned nothing. Intuitive’s revenue instead grew in each of its last three fiscal years, by 21% in the most recent one.
Intuitive’s case stays intact as long as hospitals keep doing more da Vinci procedures and keep moving to da Vinci 5. Procedure growth is the weaker of the two, since management has already said US growth moderated. Procedure growth clearly below the guide in the next quarterly report would show the US slowdown weighing on the whole business. Intuitive would then be a riskier bet that relies more on a higher P/E than on selling more.
Does This Mean You Should Act On ISRG?
Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.
There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.